Merakris Advances MTX-001 Phase 2/3 Strategy After FDA Pre-IND Meeting
Merakris says it is advancing its MTX-001 Phase 2/3 strategy following an FDA pre-IND meeting.
Related stories
Hotman Reports Interim Loss and Forecasts Full-Year Profit
Hotman reported a standalone interim net loss, compared with a loss in the prior-year period. It forecasts full-year profit growth of 3.7%.
M impact | EQUITY | Oct 30, 2026, 02:00 AM UTC
Hotman Reports Interim Ordinary Loss, Forecasts Full-Year Profit
Hotman reported an ordinary loss for the interim period, compared with an ordinary loss in the prior-year period. It forecasts full-year ordinary profit, up 6.5%.
M impact | EQUITY | Oct 30, 2026, 02:00 AM UTC
Asian session market picture: S&P 500 -1.06%, Nasdaq 100 -2.35%; USD/JPY -0.13%, WTI +2.27%, 1810 leads volume
Asian session market picture. US index futures: S and P futures is down 1.06 percent, Nasdaq futures is down 2.35 percent, Dow futures is down 0.26 percent and Russell futures is d
M impact | EQUITY | Oct 30, 2026, 02:00 AM UTC
Holley Performance Brands Acquires SXTH Element
Holley Performance Brands acquired SXTH Element, expanding its modern truck and off-road portfolio in Toyota truck and SUV performance.
M impact | EQUITY | Oct 30, 2026, 02:00 AM UTC
Theta Gold Mines Draws First US$37 Million Under US$90 Million Bond
The company says the drawdown followed an US$18.6 million equity raising.
L impact | EQUITY | Oct 30, 2026, 01:59 AM UTC
Shengyi Technology shares fall 8.7% as Jefferies cuts target
Shengyi Technology shares fell 8.7% to 85.9 yuan after opening down 4.9%, while Jefferies lowered its price target.
M impact | EQUITY | Oct 30, 2026, 01:58 AM UTC